Genomic assays of primary breast cancers can refine estimates of the risk of recurrence and the benefit of chemotherapy in patients with relatively favorable prognoses. This project, to be conducted in a large population-based sample of patients and their oncologists, will lay the foundation for understanding the use of genomic assays and the receipt of treatment in response to genomic assays in breast and other cancers.
Showing the most recent 10 out of 175 publications